Co-Director, Clinical Inflammatory Bowel Disease Cedars-Sinai Medical Center Los Angeles, California
Biologic therapies such as anti-tumor necrosis factor and anti-interleukin antibodies are used to treat a variety of immune-mediated inflammatory diseases. Even though they could lead to an elevated infection risk and rare adverse events, studies have indicated that biologics are beneficial overall in terms of long-term safety and tolerability. However, many patients do not have access to these effective treatments due to their high costs. This session will discuss biologic therapies for IMIDs, including the personalization and standardization of care.